$CNSP News

CNS Pharmaceuticals Q1 EPS $(7.30) Misses $(5.37) Estimate

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals Enters Securities Purchase Agreements For ~$22.5M Private Placement Of 650,000 Shares At $2.30 Per Share And Warrants To Purchase Up To ~9.1M Shares At Purchase Price $2.299 Per Warrant

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

CNS Pharmaceuticals Launches Global Search For Neurology And Oncology Assets, Shifts Focus From Glioblastoma

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

CNS Pharmaceuticals Appoints Steve O'Loughlin CFO, Effective March 2, Succeeding Christopher Downs

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals' New CEO Rami Levin Outlines Strategic Focus On Pipeline Optimization And Value Creation

CNS Pharmaceuticals' New CEO Rami Levin Outlines Strategic Focus On Pipeline Optimization And Value Creation

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals Appoints Rami Levin CEO, Succeeding John Climaco

CNS Pharmaceuticals CEO John Climaco Steps Down, Rami Levin Named New Chief Executive

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

CNS Pharmaceuticals Q3 EPS $(5.76) Beats $(7.09) Estimate

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap